Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. - 1999
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
[en] A residual mass after treatment of lymphoma is a clinical challenge, because it may represent vital tumor as well as tissue fibrosis. Metabolic imaging by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) offers the advantage of functional tissue characterization that is largely independent of morphologic criteria. We compared 18F-FDG PET to computed tomography (CT) in the posttreatment evaluation of 54 patients with Hodgkin's disease (HD) or intermediate/high-grade non-Hodgkin's lymphoma (NHL). Residual masses on CT were observed in 13 of 19 patients with HD and 11 of 35 patients with NHL. Five of 24 patients with residual masses on CT versus 1 of 30 patients without residual masses presented a positive 18F-FDG PET study. Relapse occurred in all 6 patients (100%) with a positive 18F-FDG PET, 5 of 19 patients (26%) with residual masses on CT but negative 18F-FDG PET, and 3 of 29 patients (10%) with negative CT scan and 18F-FDG PET studies (P
Disciplines :
Hematology
Author, co-author :
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Fassotte, Marie-France ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Najjar, F.
Paulus, P.
Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Publication date :
1999
Journal title :
Blood
ISSN :
0006-4971
eISSN :
1528-0020
Publisher :
American Society of Hematology, Washington, United States - District of Columbia
Israel O, Front D, Lam M, Ben-Haim S, Kleinhaus U, Ben-Shachar M, Robinson E, Kolodny GM: Ga-67 imaging in monitoring lymphoma response to treatment. Cancer 61:2439, 1988
Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931, 1988 (editiorial)
Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoil T, Foidart-Willems J: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxy-glucose. Eur J Nucl Med 23:1641, 1996
Warburg O, Wind F, Neglers E: On the metabolism of tumors in the body, in Warburg O (ed): Metabolism of Tumors. London, UK, Constable, 1930, p 254
Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP: Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18 F]-2-deoxy-2-fluoro-D-glucose. J Nucl Med 19:1154, 1978
Negendank WG, al-Katib AM, Karanes C, Smith MR: Lymphomas: MR imaging contrast characteristics with clinical-pathologic correlations. Radiology 177:209, 1990
Glazer HS, Lee JK, Levitt RG, Heiken JP, Ling D, Totty WG, Balfe DM, Emani B. Wasserman TH, Murphy WA: Radiation fibrosis: Differentiation from recurrent tumor by MR imaging. Radiology 156:721, 1985
Nyman RS, Rehn SM, Glimelius BL, Hagberg HE, Hemmingson AL, Sundstrom CJ: Residual mediastinal masses in Hodgkin disease: Prediction of size with MR imaging. Radiology 170:435, 1989
Hill M, Cunningham D, Mac Vicar D, Roldan A, Husband J, McCready R, Mansi J, Milan S, Hickish T: Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 11:2273, 1993
Devizzi L, Maffioli L, Bonfante V, Viviani S, Balzarini L, Gasparini M, Valagussa P, Bombardieri E, Santoro A, Bonadonna G: Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 8:S53, 1997 (suppl 1)
Bendini M, Zuiani C, Bazzocchi M, Dalpiaz G, Zaja F, Englaro E: Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study. MAGMA 4:213, 1996
Abrahamsen AF, Lien HH, Aas M, Winderen M, Hager B, Kvaloy S, Elgjo RF, Nome O: Magnetic resonance imaging and 67 gallium scan in mediastinal malignant lymphoma: A prospective pilot study. Ann Oncol 5:433, 1994
Zinzani PL, Zompatori M, Bendandi M, Battista G, Fanti S, Barbieri E, Gherlinzoni F, Rimondi MR, Frezza G, Pisi P, Merla E, Gozzetti A, Canini R, Monetti N, Babini L, Tura S: Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 22:131, 1996
Kostakoglu L, Yeh SD, Portlock C, Heelan R, Yao TJ, Niedzwiecki D, Larson SM: Validation of gallium-67-citrate single photon computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 33:345, 1992
losilevsky G, Front D, Bettman L, Hardoff R, Ben-Arieh Y: Uptake of gallium-67 citrate in [2-3H] deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med 26:278, 1985
Front D, Israel O: The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 25:60, 1995
Bekerman C, Hoffer PB, Bitran JD: The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med 14:296, 1984
Kaplan WD, Jochelson MS, Herman TS, Nadler LM, Stomper PC, Takvorian T, Andersen JW, Canellos GP: Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 8:1966, 1990
Shin MS, Ho KJ: Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin's disease: An immunologic rebound phenomenon? Cancer 51:30, 1983
Peylan-Ramu N, Haddy TB, Jones E, Horvath K, Adde MA, Magrath IT: High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol 7:1800, 1989
Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J: False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 38:888, 1997
Dohmen BM, Brugger W, Lietzenmayer R, Sökler M, Kanz L, Bares R: Evaluation of residual or recurrent malignant lymphoma by FDG-PET. Abstract Book 44th Annual Meeting of the Society of Nuclear Medicine, San Antonio, Texas. J Nucl Med 38:154P, 1997
De Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK: Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8:S57, 1997 (suppl 1 )
